Plain-English translation of NCT07417566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see how safe it is and how the body handles it. Researchers are giving healthy volunteers different doses of the medication to understand its effects before it can be considered for treating Stargardt disease, a condition that causes vision loss. The study is divided into two parts: one where participants take a single dose, and another where they take the medication daily for two weeks.
Stargardt disease is a serious inherited eye condition that can lead to significant vision problems, and there are currently limited treatment options available. This trial exists to determine whether this medication is safe and could potentially help patients with this condition in the future.
You likely qualify if…
You likely don't qualify if…
Participants will visit the research clinic multiple times over several weeks. In the first part, you would take a single dose of the medication (or placebo) on an empty stomach, then have blood samples collected and safety checks over the next 9 days. In the second part, you would take the medication (or placebo) once daily for 14 consecutive days while fasting, with regular blood tests and health monitoring throughout. The study also includes a special test where some participants take the medication after eating a fatty meal to see how food affects how the body processes it.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Heronova Pharmaceuticals
Enrollment target
~76 participants
Started
January 2026
Primary completion
December 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kang Ren
Heronova Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.